Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide

<p>Abstract</p> <p>Background </p> <p>Human CD1d-restricted, invariant natural killer T cells (iNKT) are a unique class of T lymphocytes that recognise glycolipid antigens such as α-galactosylceramide (αGalCer) and upon T cell receptor (TCR) activation produce both Th1...

Full description

Bibliographic Details
Main Authors: Besra Gurdyal S, Illarionov Petr A, Willcox Carrie R, Mura Manuela, Curbishley Stuart M, Croudace Joanne E, Adams David H, Lammas David A
Format: Article
Language:English
Published: BMC 2008-12-01
Series:BMC Immunology
Online Access:http://www.biomedcentral.com/1471-2172/9/71
id doaj-98949c4090374f7a9449fab8736e6fb2
record_format Article
spelling doaj-98949c4090374f7a9449fab8736e6fb22020-11-25T03:35:20ZengBMCBMC Immunology1471-21722008-12-01917110.1186/1471-2172-9-71Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramideBesra Gurdyal SIllarionov Petr AWillcox Carrie RMura ManuelaCurbishley Stuart MCroudace Joanne EAdams David HLammas David A<p>Abstract</p> <p>Background </p> <p>Human CD1d-restricted, invariant natural killer T cells (iNKT) are a unique class of T lymphocytes that recognise glycolipid antigens such as α-galactosylceramide (αGalCer) and upon T cell receptor (TCR) activation produce both Th1 and Th2 cytokines. iNKT cells expand when cultured <it>in-vitro </it>with αGalCer and interleukin 2 (IL-2) in a CD1d-restricted manner. However, the expansion ratio of human iNKT cells varies between individuals and this has implications for attempts to manipulate this pathway therapeutically. We have studied a panel of twenty five healthy human donors to assess the variability in their <it>in-vitro </it>iNKT cell expansion responses to stimulation with CD1d ligands and investigated some of the factors that may influence this phenomenon.</p> <p>Results </p> <p>Although all donors had comparable numbers of circulating iNKT cells their growth rates <it>in-vitro </it>over 14 days in response to a range of CD1d ligands and IL-2 were highly donor-dependent. Two reproducible donor response patterns of iNKT expansion were seen which we have called 'strong' or 'poor' iNKT responders. Donor response phenotype did not correlate with age, gender, frequency of circulating iNKT, or with the CD1d ligand utilised. Addition of exogenous recombinant human interleukin 4 (IL-4) to 'poor' responder donor cultures significantly increased their iNKT proliferative capacity, but not to levels equivalent to that of 'strong' responder donors. However in 'strong' responder donors, addition of IL-4 to their cultures did not significantly alter the frequency of iNKT cells in the expanded CD3<sup>+ </sup>population.</p> <p>Conclusion </p> <p>(i) <it>in-vitro </it>expansion of human iNKT cells in response to CD1d ligand activation is highly donor variable, (ii) two reproducible patterns of donor iNKT expansion were observed, which could be classified into 'strong' and 'poor' responder phenotypes, (iii) donor iNKT response phenotypes did not correlate with age, gender, frequency of circulating iNKT cells, or with the CD1d ligand utilised, (iv) addition of IL-4 to 'poor' but not 'strong' responder donor cultures significantly increased their <it>in-vitro </it>iNKT cell expansion to αGalCer.</p> http://www.biomedcentral.com/1471-2172/9/71
collection DOAJ
language English
format Article
sources DOAJ
author Besra Gurdyal S
Illarionov Petr A
Willcox Carrie R
Mura Manuela
Curbishley Stuart M
Croudace Joanne E
Adams David H
Lammas David A
spellingShingle Besra Gurdyal S
Illarionov Petr A
Willcox Carrie R
Mura Manuela
Curbishley Stuart M
Croudace Joanne E
Adams David H
Lammas David A
Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
BMC Immunology
author_facet Besra Gurdyal S
Illarionov Petr A
Willcox Carrie R
Mura Manuela
Curbishley Stuart M
Croudace Joanne E
Adams David H
Lammas David A
author_sort Besra Gurdyal S
title Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
title_short Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
title_full Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
title_fullStr Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
title_full_unstemmed Identification of distinct human invariant natural killer T-cell response phenotypes to alpha-galactosylceramide
title_sort identification of distinct human invariant natural killer t-cell response phenotypes to alpha-galactosylceramide
publisher BMC
series BMC Immunology
issn 1471-2172
publishDate 2008-12-01
description <p>Abstract</p> <p>Background </p> <p>Human CD1d-restricted, invariant natural killer T cells (iNKT) are a unique class of T lymphocytes that recognise glycolipid antigens such as α-galactosylceramide (αGalCer) and upon T cell receptor (TCR) activation produce both Th1 and Th2 cytokines. iNKT cells expand when cultured <it>in-vitro </it>with αGalCer and interleukin 2 (IL-2) in a CD1d-restricted manner. However, the expansion ratio of human iNKT cells varies between individuals and this has implications for attempts to manipulate this pathway therapeutically. We have studied a panel of twenty five healthy human donors to assess the variability in their <it>in-vitro </it>iNKT cell expansion responses to stimulation with CD1d ligands and investigated some of the factors that may influence this phenomenon.</p> <p>Results </p> <p>Although all donors had comparable numbers of circulating iNKT cells their growth rates <it>in-vitro </it>over 14 days in response to a range of CD1d ligands and IL-2 were highly donor-dependent. Two reproducible donor response patterns of iNKT expansion were seen which we have called 'strong' or 'poor' iNKT responders. Donor response phenotype did not correlate with age, gender, frequency of circulating iNKT, or with the CD1d ligand utilised. Addition of exogenous recombinant human interleukin 4 (IL-4) to 'poor' responder donor cultures significantly increased their iNKT proliferative capacity, but not to levels equivalent to that of 'strong' responder donors. However in 'strong' responder donors, addition of IL-4 to their cultures did not significantly alter the frequency of iNKT cells in the expanded CD3<sup>+ </sup>population.</p> <p>Conclusion </p> <p>(i) <it>in-vitro </it>expansion of human iNKT cells in response to CD1d ligand activation is highly donor variable, (ii) two reproducible patterns of donor iNKT expansion were observed, which could be classified into 'strong' and 'poor' responder phenotypes, (iii) donor iNKT response phenotypes did not correlate with age, gender, frequency of circulating iNKT cells, or with the CD1d ligand utilised, (iv) addition of IL-4 to 'poor' but not 'strong' responder donor cultures significantly increased their <it>in-vitro </it>iNKT cell expansion to αGalCer.</p>
url http://www.biomedcentral.com/1471-2172/9/71
work_keys_str_mv AT besragurdyals identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide
AT illarionovpetra identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide
AT willcoxcarrier identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide
AT muramanuela identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide
AT curbishleystuartm identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide
AT croudacejoannee identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide
AT adamsdavidh identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide
AT lammasdavida identificationofdistincthumaninvariantnaturalkillertcellresponsephenotypestoalphagalactosylceramide
_version_ 1724555088545972224